<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801199</url>
  </required_header>
  <id_info>
    <org_study_id>CRSC18005</org_study_id>
    <nct_id>NCT04801199</nct_id>
  </id_info>
  <brief_title>Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus</brief_title>
  <official_title>Prospective, Randomized, Double Blind, Parallel Group, Two Arm, Comparative, Multicenter, Clinical Study to Compare Efficacy and Safety of Oral CPL-2009-0031 140 mg of Cadila Pharmaceutical Limited, India Against Innovator Sitagliptin 100 mg in Patients With Uncontrolled Type-2 Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Pharnmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cadila Pharnmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm,&#xD;
      Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and&#xD;
      tolerability of oral CPL-2009-0031 140 mg in comparison with Sitagliptin 100 mg in patients&#xD;
      with Uncontrolled Type-2 Diabetes Mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase-III trial, after due consent and completing initial 2-weeks of placebo run-in&#xD;
      period with diet, exercise and counseling, eligible patients with uncontrolled T2DM will be&#xD;
      randomized in balance to receive either once daily oral CPL-2009-0031 140 mg or Sitagliptin&#xD;
      100 mg.&#xD;
&#xD;
      After completing 12 weeks of study post-randomization for regulatory submission, patients&#xD;
      will be instructed for continuation of extension phase of treatment and follow up upto 36&#xD;
      weeks.&#xD;
&#xD;
      HbA1c will be measured at screening, baseline, 12 weeks, 24 weeks and 36 weeks of treatment.&#xD;
      While, Fasting Blood Sugar (FBS) and Postprandial Blood Sugar (PPBS) measurement will be&#xD;
      performed every 2 weeks.&#xD;
&#xD;
      The enrolled patients will be monitored for safety (AE and SAE) throughout the study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 26, 2020</start_date>
  <completion_date type="Actual">February 11, 2021</completion_date>
  <primary_completion_date type="Actual">January 13, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigator, patient, study staff, data monitors and database personnel will be blinded to the study treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c level</measure>
    <time_frame>Baseline, 12 weeks, 24 weeks and 36 weeks from onset of therapy</time_frame>
    <description>To evaluate HbA1c levels between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Sugar (FBS) level</measure>
    <time_frame>Every 2 week till 12 weeks and every 4 weeks between 12 weeks to 36 weeks from onset of therapy</time_frame>
    <description>To compare Fasting Blood Sugar between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Blood Sugar (PPBS) level</measure>
    <time_frame>Every 2 week till 12 weeks and every 4 weeks between 12 weeks to 36 weeks from onset of therapy</time_frame>
    <description>To compare Fasting Blood Sugar between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Serious Adverse Events</measure>
    <time_frame>From randomization to end of 12 week, 24 week and 36-weeks therapy</time_frame>
    <description>Determination of safety and tolerability of CPL-2009-0031 140 mg versus Sitagliptin 100 mg based on Frequency of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemic events</measure>
    <time_frame>From randomization to end of 12 week, 24 week and 36-weeks therapy</time_frame>
    <description>Determine number and severity of hypoglycemic events of CPL-2009-0031 140 mg versus Sitagliptin 100 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>From randomization to end of 12 week, 24 week and 36-weeks therapy</time_frame>
    <description>Determine frequency and severity of adverse events of CPL-2009-0031 140 mg versus Sitagliptin 100 mg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Uncontrolled Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CPL-2009-0031 140 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Oral tablet containing 140 mg of CPL-2009-0031, Once daily for 36-weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose, Oral tablet containing 100 mg of Sitagliptin, Once daily for 36-weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPL-2009-0031 140 mg</intervention_name>
    <description>Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.</description>
    <arm_group_label>CPL-2009-0031 140 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100mg</intervention_name>
    <description>Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adult patient of 18-65 years with uncontrolled type 2 diabetes&#xD;
             Mellitus (T2DM).&#xD;
&#xD;
          -  Patients with HbA1c ≥ 7 to 10 and those on oral hypoglycemic agents ≤ 2 other than&#xD;
             Insulin and Gliptins.&#xD;
&#xD;
          -  BMI in the range of 18.5 - 35 kg/m2.&#xD;
&#xD;
          -  All patients must be willing to give informed consent and can understand &amp; complying&#xD;
             protocol requirement.&#xD;
&#xD;
          -  Patients who are in good health at the time of entry into the study as determined by&#xD;
             medical, medication and hypersensitivity histories, clinical examination, vital sign&#xD;
             measurements, chest X-ray, 12-lead ECG measurement and clinical judgment of the&#xD;
             investigator.&#xD;
&#xD;
          -  Documented negative test for human immuno virus (HIV), Hepatitis B surface antigen&#xD;
             (HBsAg) and Hepatitis C virus (HCV).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who are on insulin and not ready for wash out of 3 months.&#xD;
&#xD;
          -  Those who are on gliptin and not ready for wash out of 3 months.&#xD;
&#xD;
          -  Those with a history of severe ketosis, diabetic coma or pre-coma, or type 1 diabetes.&#xD;
&#xD;
          -  Those scheduled for or who had undergone surgery.&#xD;
&#xD;
          -  Those with a severe infection or serious injury&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Hypersensitivity and contraindication to DPP-IV inhibitors or excipients of&#xD;
             investigational drug formulation.&#xD;
&#xD;
          -  Hypertensive patients with blood pressure ≥160/100 mm of Hg.&#xD;
&#xD;
          -  History of ischemic heart disease (as evident from ECG), stroke and/or transient&#xD;
             ischemic attack.&#xD;
&#xD;
          -  Debilitating neurological or psychiatric disorders&#xD;
&#xD;
          -  History or currently consuming abusing drugs or alcohol.&#xD;
&#xD;
          -  Serious hepatic or renal impairment (liver dysfunction as evidenced by SGPT/SGOT level&#xD;
             of 2.5 X ULN and renal dysfunction as evidenced by creatinine level 2.5 X ULN).&#xD;
&#xD;
          -  Patient with abnormal clinical chemistry, hematology or urinalysis results that are&#xD;
             considered clinically significant by the investigator or the sponsor.&#xD;
&#xD;
          -  Patient has any concurrent illness which, in the opinion of the investigator or&#xD;
             coinvestigator, may interfere with treatment or evaluation of safety or completion of&#xD;
             this study.&#xD;
&#xD;
          -  In the investigator's judgment, the patient is unable to adhere to the treatment&#xD;
             regimen, protocol procedures or study requirements.&#xD;
&#xD;
          -  Participation in another clinical trial in the past 3 months.&#xD;
&#xD;
          -  Patients with history of smoking or currently having smoking habit will not be&#xD;
             included in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Avhad, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Cadila Pharmaceutical Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A C Subba Reddy Government Medical College and Hospital</name>
      <address>
        <city>Nellore</city>
        <state>Andhra Pradesh</state>
        <zip>524004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Hospital</name>
      <address>
        <city>Guwahati</city>
        <state>Assam</state>
        <zip>781006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSG Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Diabetes Centre</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dhadiwal Hospital</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashirwad Hospital &amp; Research Centre</name>
      <address>
        <city>Ulhasnagar</city>
        <state>Maharashtra</state>
        <zip>421004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.P. Medical College and A.G. Hospital</name>
      <address>
        <city>Bīkaner</city>
        <state>Rajasthan</state>
        <zip>334001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhandari Clinic &amp; Research Centre</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjivini Lung Centre</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226010,</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nilratan Sircar Medical College &amp; Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Line Diagnostic Centre cum Nursing Home</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>70001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital International Ltd</name>
      <address>
        <city>Gandhinagar</city>
        <zip>382428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=32963&amp;EncHid=&amp;modid=&amp;compid=%27,%2732963det%27</url>
    <description>Clinical trial database uploaded on Clinical Trial Registry of India (CTRI)</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

